AL Amyloidosis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “AL Amyloidosis – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AL Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
AL Amyloidosis: Overview
Amyloidosis is a rare and serious protein deposition disease. It is caused by an abnormal protein called amyloid that builds up in tissues or organs. As the amount of amyloid protein deposits increase in a tissue or organ, they interfere with the tissue or organ’s healthy function. Eventually, the amyloid protein deposits cause symptoms and organ failure. This is the most common type of amyloidosis in the United States. The amyloid proteins that build up in the tissues in this condition are known as light chains. They can either be kappa or lambda light chains. AL amyloidosis is a disorder of the plasma cells. Plasma cells are a type of white blood cell responsible for the production of immunoglobulins or antibodies, which are a type of protein that fights infection. In AL amyloidosis, the light chain proteins are misshapen and produced in excess. They deposit in tissues and can damage 1 or more organs. The heart, kidneys, nerves, and gastrointestinal system are the most common organs affected. Diagnostic testing for AL amyloidosis involves blood tests, urine tests and biopsies. Blood and/or urine tests can indicate signs of the amyloid protein, but only bone marrow tests or other small biopsy samples of tissue or organs can positively confirm the diagnosis of amyloidosis. Treatment for AL amyloidosis is tailored to the patient with their individual health in mind. The type of treatment is based upon disease progression and seriousness of the patient’s organ, tissue and nerve involvement. Treatment plans are two-fold: Supportive treatment – treating your symptoms and organ damage; and, Source treatment – slowing down, or stopping, the overproduction of amyloid at the source of the disease.
'AL Amyloidosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the AL Amyloidosis pipeline landscape is provided which includes the disease overview and AL Amyloidosis treatment guidelines. The assessment part of the report embraces, in depth AL Amyloidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, AL Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the AL Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AL Amyloidosis Emerging Drugs
Further product details are provided in the report……..
AL Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different AL Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
AL Amyloidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses AL Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AL Amyloidosis drugs.
AL Amyloidosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “AL Amyloidosis – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AL Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
AL Amyloidosis: Overview
Amyloidosis is a rare and serious protein deposition disease. It is caused by an abnormal protein called amyloid that builds up in tissues or organs. As the amount of amyloid protein deposits increase in a tissue or organ, they interfere with the tissue or organ’s healthy function. Eventually, the amyloid protein deposits cause symptoms and organ failure. This is the most common type of amyloidosis in the United States. The amyloid proteins that build up in the tissues in this condition are known as light chains. They can either be kappa or lambda light chains. AL amyloidosis is a disorder of the plasma cells. Plasma cells are a type of white blood cell responsible for the production of immunoglobulins or antibodies, which are a type of protein that fights infection. In AL amyloidosis, the light chain proteins are misshapen and produced in excess. They deposit in tissues and can damage 1 or more organs. The heart, kidneys, nerves, and gastrointestinal system are the most common organs affected. Diagnostic testing for AL amyloidosis involves blood tests, urine tests and biopsies. Blood and/or urine tests can indicate signs of the amyloid protein, but only bone marrow tests or other small biopsy samples of tissue or organs can positively confirm the diagnosis of amyloidosis. Treatment for AL amyloidosis is tailored to the patient with their individual health in mind. The type of treatment is based upon disease progression and seriousness of the patient’s organ, tissue and nerve involvement. Treatment plans are two-fold: Supportive treatment – treating your symptoms and organ damage; and, Source treatment – slowing down, or stopping, the overproduction of amyloid at the source of the disease.
'AL Amyloidosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the AL Amyloidosis pipeline landscape is provided which includes the disease overview and AL Amyloidosis treatment guidelines. The assessment part of the report embraces, in depth AL Amyloidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, AL Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence AL Amyloidosis R&D. The therapies under development are focused on novel approaches to treat/improve AL Amyloidosis.
This segment of the AL Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AL Amyloidosis Emerging Drugs
- CAEL-101: Caelum Biosciences
- Ixazomib: Takeda
- Belantamab mafodotin: GlaxoSmithKline
Further product details are provided in the report……..
AL Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different AL Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in AL Amyloidosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
AL Amyloidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses AL Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AL Amyloidosis drugs.
AL Amyloidosis Report Insights
- AL Amyloidosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing AL Amyloidosis drugs?
- How many AL Amyloidosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of AL Amyloidosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AL Amyloidosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AL Amyloidosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
AL Amyloidosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
CAEL-101: Caelum Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Belantamab mafodotin: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Genakumab: GeneScience Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
AL Amyloidosis Key Companies
AL Amyloidosis Key Products
AL Amyloidosis- Unmet Needs
AL Amyloidosis- Market Drivers and Barriers
AL Amyloidosis- Future Perspectives and Conclusion
AL Amyloidosis Analyst Views
AL Amyloidosis Key Companies
Appendix
Executive Summary
AL Amyloidosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
CAEL-101: Caelum Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Belantamab mafodotin: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Genakumab: GeneScience Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
AL Amyloidosis Key Companies
AL Amyloidosis Key Products
AL Amyloidosis- Unmet Needs
AL Amyloidosis- Market Drivers and Barriers
AL Amyloidosis- Future Perspectives and Conclusion
AL Amyloidosis Analyst Views
AL Amyloidosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for AL Amyloidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for AL Amyloidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for AL Amyloidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for AL Amyloidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
